Prophylactic Haloperidol Effects on Long-term Quality of Life in Critically Ill Patients at High Risk for Delirium: Results of the REDUCE Study
Published: Anesthesiology 2019; 131: 328-335
Authors: Paul J. T. Rood, R.N., M.Sc.; Marieke Zegers, Ph.D.; Arjen J. C. Slooter, M.D., Ph.D.; Albert Beishuizen, M.D., Ph.D.; Koen S. Simons, M.D., Ph.D.; Peter H. J. van der Voort, M.D., Ph.D.; Meta C. E. van der Woude, M.D.; Peter E. Spronk, M.D., Ph.D.; Johannes G. van der Hoeven, M.D., Ph.D.; Peter Pickkers, M.D., Ph.D.; Mark van den Boogaard, R.N., Ph.D.
The present multicentre randomized clinical trial investigated the role of prophylactic haloperidol for delirium on long-term quality of life.
This is a sub-study conducted in 9 /21 ICUs in the REDUCE study.
- Delirium, a common disorder in the intensive care unit (ICU), is associated with impaired short-term and long-term outcomes.
- The authors randomized adult patients who were delirium-free to receive prophylactic haloperidol or placebo.
- The physical and mental long-term quality of life using a short form of 12 questionnaire, the primary outcome, did not differ between the two groups.
- Increasing age, medical and trauma admission, baseline quality of life score, and the duration of sedation-induced coma were predictors for long-term quality of life.
- Therefore, the authors concluded that haloperidol does not improve the long-term quality of life in critically-ill patients who are at high risk for delirium.
Check this interesting study and look for the results: would this be a plus or change your practice?
Follow us and join the upcoming EACTA polls on Facebook, Instagram, Twitter and LinkedIn: we look forward to hearing from you!